Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder
Study sponsor: Vanda Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-09-07Actual
Enrollment · participants417Actual
Source updated2024-04-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.